Vaccine Research Study
Researchers at Beth Israel Deaconess Medical Center are evaluating the safety and tolerability of a new vaccine.
Fast Facts
Individuals ages 18-65
Received at least 1 COVID-19 immunization
Compensation Provided
Conducted in Boston, MA
Study Background
Researchers at Beth Israel Deaconess Medical Center are evaluating the safety and tolerability of a new vaccine.
Our primary focus is to evaluate the safety and tolerability of the IMNN-101 vaccine in healthy adults, while also investigating the immune system’s response to this experimental vaccine.
Through this study, we aim to assess the potential side effects and adverse reactions associated with the administration of IMNN-101, ensuring its safety profile in the target population.
By closely monitoring the immune response elicited by the vaccine, we seek to understand its effectiveness in stimulating the body’s defenses against specific pathogens or antigens. This dual approach allows us to comprehensively evaluate the vaccine’s safety profile and its ability to induce an immune response, providing valuable insights into its potential as a preventive measure against infectious diseases.
Study Background
Researchers at Beth Israel Deaconess Medical Center are evaluating the safety and tolerability of a new vaccine.
Our primary focus is to evaluate the safety and tolerability of the IMNN-101 vaccine in healthy adults, while also investigating the immune system’s response to this experimental vaccine.
Through this study, we aim to assess the potential side effects and adverse reactions associated with the administration of IMNN-101, ensuring its safety profile in the target population.
By closely monitoring the immune response elicited by the vaccine, we seek to understand its effectiveness in stimulating the body’s defenses against specific pathogens or antigens. This dual approach allows us to comprehensively evaluate the vaccine’s safety profile and its ability to induce an immune response, providing valuable insights into its potential as a preventive measure against infectious diseases.
Additional Information
You may qualify for this study if you meet the following criteria:
Inclusion Criteria
- Healthy adults between the ages of 18 and 65
- Previously received at least one COVID-19 immunization with the last dose at least (greater than or equal to) four months prior to enrollment
- If a person of childbearing potential, willing to use effective methods of contraception
- Breast-feeding or pregnant
- History of COVID-19 infection within 3 months of screening
- Immunocompromising conditions and medications, clotting disorders, and cardiovascular conditions such as heart failure, myocarditis, and pericarditis
If you participate in this study, you can expect the following:
Participants can earn up to $825 in compensation for completion of this study.
There is no cost for you to participate in our research study.